Detection of T lymphocyte subsets and mIL-2R on surface of PBMC in patients with hepatitis B

Table 1 Detection of T lymphocyte subsets and mIL-2R in PBMC of patients with hepatitis B (^-x±s, %)

Group	n	CD3+	CD4+	CD8+	CD4+/CD8+	mIL-2R
						Silent	Induced
Control	30	65.96 ± 6.54a	41.73 ± 6.40b	30.02 ± 4.54c	1.44 ± 0.31d	4.52 ± 1.49e	37.95 ± 3.00f
Anti-HBs (+)	10	66.34 ± 5.16	42.82 ± 6.52	29.03 ± 4.50	1.51 ± 0.27	5.06 ± 1.45	40.26 ± 3.10
NBD	20	65.80 ± 6.92	41.20 ± 6.36	30.45 ± 4.62	1.39 ± 0.33	4.24 ± 1.52	36.30 ± 2.95
Hepatitis B	196	42.20 ± 6.01a	38.17 ± 5.93b	39.86 ± 6.36c	0.91 ± 0.28d	3.47 ± 1.55e	34.03 ± 2.94f
A HBsAg (+)	24	58.83 ± 7.44g	41.34 ± 5.16h	35.34 ± 7.15i	1.20 ± 0.33j	3.94 ± 1.75k	35.05 ± 3.05l
AH	22	57.38 ± 7.73g	40.21 ± 6.12h	39.47 ± 6.25i	1.01 ± 0.30j	3.67 ± 1.68k	34.22 ± 2.25l
SCH	46	38.54 ± 7.56g	39.56 ± 6.44h	41.10 ± 7.64i	0.98 ± 0.31j	3.44 ± 1.40k	31.96 ± 3.80l
MCH	37	40.14 ± 5.85g	37.22 ± 5.38h	41.45 ± 6.23i	0.88 ± 0.25j	3.25 ± 1.50k	32.81 ± 2.76l
SCH	20	40.01 ± 6.23g	35.51 ± 6.33h	42.86 ± 5.58i	0.81 ± 0.22j	3.06 ± 1.56k	33.83 ± 3.52l
SH	15	37.85 ± 6.54g	34.57 ± 6.20h	42.92 ± 5.65i	0.80 ± 0.21j	3.95 ± 1.54k	33.85 ± 2.65l
PC	18	38.72 ± 6.22g	36.11 ± 4.23h	41.89 ± 8.98i	0.90 ± 0.19j	3.31 ± 1.60k	31.55 ± 2.34l
HC	8	39.44 ± 6.78g	34.15 ± 5.50h	43.46 ± 7.88i	0.83 ± 0.24j	3.36 ± 1.68k	30.38 ± 2.15l

^at = 19.9295, ^aP < 0.001.

^bt = 3.0300, ^bP < 0.01.

^ct = 8.1551, ^cP < 0.001.

^dt = 9.5153, ^dP < 0.001.

^et = 3.4722, ^eP < 0.001.

^ft = 6.7832, ^fP < 0.001.

^gF = 3723.18, ^gP < 0.01.

^hF = 130.43, ^hP < 0.01.

ⁱF = 54.01, ⁱP < 0.01.

^jF = 2.99, ^jP < 0.05.

^kF = 7.16, ^kP < 0.01.

^lF = 1.60, ^lP > 0.05. NBD: Normal blood donors, A HBsAg (+): Asymptomatic HBsAg (+), AH: Acute hepatitis, SCH: Slight chronic hepatitis, MCH: Moderate chronic hepatitis, SCH: Severe chronic hepatitis, SH: Severe hepatitis, PC: Posthepatitic cirrhosis, HC: Hepatocellular carcinoma.